538 studies on GIP agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This pilot study is critically important because it addresses a significant clinical challenge: achieving healthy weight loss in older adults without compromising vital muscle and bone mass. If Tirzepatide can demonst…
This study provides compelling evidence that tirzepatide, a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, is significantly more effective than semaglutid…
This research provides compelling evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, may offer a novel therapeutic approach to improve outcomes for obese patients after TAVR. By significantly reducing subcl…
This study provides compelling evidence that combining GLP-1 receptor agonists with progestin therapy could be a highly effective and safe fertility-sparing treatment for EIN and early-stage endometrial cancer. The si…
Improved device design, particularly through automation, can significantly enhance patient safety and adherence for chronic conditions requiring frequent self-injection, such as type 2 diabetes and obesity. Reducing c…
The systematic review identified a consistent, albeit variable, reporting of hair loss among patients receiving GLP-1 receptor agonists. Across the analyzed studies, the incidence of alopecia ranged from approximately…
This systematic review provides compelling evidence that incretin-based therapies offer superior body composition benefits, promoting greater fat loss while better preserving crucial lean muscle mass, which is vital f…
The investigation of eloralintide, particularly in combination with tirzepatide, represents a significant step in developing next-generation treatments for obesity. If eloralintide demonstrates a favorable safety and …
Understanding the drug effect of Tirzepatide on musculoskeletal abnormalities is critical for optimizing obesity treatment strategies. This research could provide evidence for the necessity of combining GLP-1 therapie…
This study is significant because it explores a novel therapeutic approach for two intertwined and devastating conditions: Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease. If successful, tirzepatid…
This feasibility study could provide crucial preliminary evidence for a novel and highly effective treatment strategy for obesity-related hypertension in a vulnerable young adult population. If successful, it could es…
This study provides crucial insights for plastic surgeons and patients, indicating that GLP-1 RA-induced weight loss may be associated with a slightly lower incidence of minor complications following body contouring s…
This study provides strong evidence that GLP-1 Receptor Agonists, exemplified by semaglutide, can directly improve cardiac function and clinical outcomes in patients with HFrEF, beyond their established metabolic bene…
This systematic review underscores the transformative potential of GLP-1 receptor agonists in the management of obesity and its associated health complications. The consistent and significant weight loss observed, cou…
This review highlights the significant potential of GLP-1 RAs as a novel adjunctive therapy for Cystic Fibrosis, offering benefits beyond their established role in diabetes management. Their pleiotropic effects could …
This research highlights that tirzepatide offers substantial cardiovascular benefits, specifically in reducing blood pressure and improving heart function, independent of its known metabolic effects. The observed modu…
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
Understanding the nuanced differences in how GLP-1 receptor agonists and gastric bypass surgery affect body composition is crucial for optimizing treatment strategies for obesity. If GLP-1 RAs can achieve similar bene…
This research is highly significant as it targets a critical unmet need in Type 2 Diabetes management: patients who do not achieve adequate glycemic control even with potent GLP-1 or GLP-1/GIP receptor agonists. LY345…
This Phase 2a study is crucial because it targets a specific genetic subtype of MASLD that is often more aggressive and difficult to treat. ALN-PNP works by reducing the PNPLA3 protein, which is implicated in liver fa…
This study provides compelling evidence that Tirzepatide offers substantial cardiovascular protection beyond its established glucose-lowering and weight-loss benefits, positioning it as a critical therapy for patients…
This study provides compelling evidence that tirzepatide, a dual GLP-1 and GIP receptor agonist, offers substantial cardiovascular protection beyond its established glycemic control and weight loss benefits in patient…
This study provides compelling evidence that Tirzepatide, a dual GIP and GLP-1 receptor agonist, significantly improves cardiovascular outcomes in patients with Type 2 Diabetes and high cardiovascular risk. This posit…
This study provides compelling evidence that tirzepatide offers significant and broad cardiovascular protection beyond its established glycemic and weight-loss benefits, positioning it as a leading therapy for Type 2 …
This landmark study provides compelling evidence that Tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, offers substantial cardiovascular prot…
These findings are profoundly significant, as they establish Tirzepatide as a potent agent for cardiovascular risk reduction in patients with Type 2 Diabetes and existing cardiovascular disease, moving beyond its know…
The findings from SURPASS-CVOT establish tirzepatide as a potent therapeutic agent for reducing cardiovascular risk in patients with type 2 diabetes, offering benefits beyond its metabolic effects. This is particularl…
GLP-1 RAs represent a highly promising pharmacological approach for managing prediabetes and actively preventing its progression to type 2 diabetes. Their dual action on glucose control and weight loss addresses key p…
This trial is crucial because it seeks to establish tirzepatide as a novel therapeutic option specifically for the reproductive and metabolic challenges faced by women with PCOS. If successful, the findings could sign…
The MAINTAIN study addresses a critical unmet need in obesity management, offering a potential solution to the widespread problem of weight regain after discontinuing GLP-1 RAs. GFMA could provide a durable, non-pharm…
Understanding tirzepatide's effects on skeletal muscle is critically important, as preserving muscle mass during weight loss is a key challenge, especially in obesity. If tirzepatide can mitigate muscle loss or even i…
This study is crucial for understanding Tirzepatide's long-term efficacy and safety outside of highly controlled clinical trial environments. If successful, the findings could significantly inform clinical guidelines …
This study provides compelling evidence that tirzepatide, when added to basal insulin, offers a highly effective strategy for achieving robust glycemic control and significant weight loss in Chinese patients with Type…
This novel evidence strongly suggests that tirzepatide could represent a groundbreaking therapeutic strategy for cocaine use disorder (CUD). Its dual action on GLP-1 and GIP receptors appears to modulate reward pathwa…
This first-of-its-kind case report strongly suggests that Tirzepatide, a dual GLP-1/GIP receptor agonist, may offer a novel and highly effective therapeutic avenue for Lichen Planus. The observed complete remission an…
This study underscores the increasing integration of GLP-1 RAs into the clinical management pathway for patients with severe obesity and related comorbidities who are considering sleep surgery. The observed significan…
Understanding GIP's long-term effects on bone is critically important given the widespread use of GIP receptor (GIPR) agonists like tirzepatide for obesity and type 2 diabetes, conditions often associated with comprom…
This study holds significant promise as it could identify a new, effective pharmacological treatment for severe forms of obesity like Prader-Willi Syndrome and hypothalamic obesity, which currently have limited therap…
This study is crucial as it addresses a significant unmet need for effective anti-obesity treatments in adult congenital heart disease (ACHD) patients, a population often excluded from major clinical trials. If succes…
The widespread adoption of GLP-1 receptor agonists means plastic surgeons are increasingly encountering patients with significant, rapid weight loss, necessitating a paradigm shift in surgical planning. This review pr…
This comprehensive meta-analysis provides strong evidence that Tirzepatide, a dual GIP/GLP-1 receptor agonist, offers superior glycemic control and weight loss benefits compared to Dulaglutide, a selective GLP-1 recep…